Levofloxacin vs Moxifloxacin
Overview
Both levofloxacin and moxifloxacin are respiratory fluoroquinolones used for CAP and other respiratory tract infections. Moxifloxacin adds anaerobic activity but cannot be used for UTI. Levofloxacin maintains urinary efficacy.
Mechanism of Action
Both inhibit DNA gyrase and topoisomerase IV. Moxifloxacin's C8-methoxy group provides greater anaerobic activity. Both are concentration-dependent antibiotics.
Antimicrobial Spectrum
Levofloxacin: excellent S. pneumoniae, moderate Pseudomonas, excellent atypicals, no anaerobes. Moxifloxacin: similar to levofloxacin plus excellent anaerobic coverage, better S. aureus, no Pseudomonas.
Clinical Comparison
For CAP: both guideline-recommended as monotherapy (IDSA/ATS). For complicated intra-abdominal infections: moxifloxacin can be used as monotherapy (anaerobic coverage); levofloxacin requires addition of metronidazole. For UTI: levofloxacin only.
QTc
Both prolong QTc; moxifloxacin more than levofloxacin.
Key Takeaways
- Both respiratory FQs for CAP; moxifloxacin adds anaerobic coverage
- Levofloxacin: can treat UTI; moxifloxacin cannot
- Moxifloxacin: greater QTc risk
Fazit
For CAP, both are equivalent first-line options. Moxifloxacin is preferred when anaerobic coverage is needed without a second agent. Levofloxacin is preferred when UTI or Pseudomonas coverage is required. QTc risk is higher with moxifloxacin.